YNY Nakaya

Y Nakaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Y Nakaya has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • H Naito

    Discovery Research Laboratories, Nippon Shinyaku Co. Ltd, Kyoto, Japan

    2 shared publications
  • K Shimoda

    Department of Gastroenterology and Hematology, Faculty of Medicine, Miyazaki University, Miyazaki, Japan

    2 shared publications
  • Kotaro Shide

    Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

    2 shared publications
  • T Horio

    Discovery Research Laboratories, Nippon Shinyaku Co. Ltd, Kyoto, Japan

    2 shared publications
  • T Niwa

    Discovery Research Laboratories, Nippon Shinyaku Co. Ltd, Kyoto, Japan

    2 shared publications
  • H Shibayama

    Discovery Research Laboratories, Nippon Shinyaku Co., Ltd, Kyoto, Japan

    1 shared publication

Latest Publications

  • Open Access

    Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis

    by Y Nakaya, K Shide, H Naito, T Niwa, T Horio, J Miyake, K Shimoda

    A single somatic mutation, V617F, in Janus kinase 2 (JAK2) is one of the causes of myeloproliferative neoplasms (MPNs), including primary myelofibrosis, and the JAK2V617F mutant kinase is a therapeutic target in MPN. However, inhibition of wild-type (WT) JAK2 can decrease the erythrocyte or platelet (PLT) count. Our selective JAK2 inhibitor, NS-018, suppressed the growth of Ba/F3 cells harboring JAK2V617F more strongly than that of cells harboring WT JAK2. The 4.3-fold JAK2V617F selectivity of NS-018 is higher than the 1.0- to 2.9-fold selectivity of seven existing JAK2 inhibitors. NS-018 also inhibited erythroid colony formation in JAK2V617F transgenic mice at significantly lower concentrations than in WT mice. In keeping with the above results, in a JAK2V617F bone marrow transplantation mouse model with a myelofibrosis-like disease, NS-018 reduced leukocytosis and splenomegaly, improved bone marrow fibrosis and prolonged survival without decreasing the erythrocyte or PLT count in the peripheral blood. By exploring the X-ray co-crystal structure of NS-018 bound to JAK2, we identified unique hydrogen-bonding interactions between NS-018 and Gly993 as a plausible explanation for its JAK2V617F selectivity. These results suggest that NS-018 will have therapeutic benefit for MPN patients through both its efficacy and its reduced hematologic adverse effects.


  • Open Access

    Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms

    by Y Nakaya, K Shide, T Niwa, J Homan, S Sugahara, T Horio, K Kuramoto, T Kotera, H Shibayama, K Hori, et al.

    Aberrant activation of Janus kinase 2 (JAK2) caused by somatic mutation of JAK2 (JAK2V617F) or the thrombopoietin receptor (MPLW515L) plays an essential role in the pathogenesis of myeloproliferative neoplasms (MPNs), suggesting that inhibition of aberrant JAK2 activation would have a therapeutic benefit. Our novel JAK2 inhibitor, NS-018, was highly active against JAK2 with a 50% inhibition (IC50) of TEL–JAK2 fusion gene; IC50=11–120 nM), but showed only minimal cytotoxicity against most other hematopoietic cell lines without a constitutively activated JAK2. Furthermore, NS-018 preferentially suppressed in vitro erythropoietin-independent endogenous colony formation from polycythemia vera patients. NS-018 also markedly reduced splenomegaly and prolonged the survival of mice inoculated with Ba/F3 cells harboring JAK2V617F. In addition, NS-018 significantly reduced leukocytosis, hepatosplenomegaly and extramedullary hematopoiesis, improved nutritional status, and prolonged survival in JAK2V617F transgenic mice. These results suggest that NS-018 will be a promising candidate for the treatment of MPNs.